Advertisement

Ads Placeholder
Loading...

Neuronetics, Inc.

STIMNASDAQ
Healthcare
Medical - Diagnostics & Research
$1.52
$0.03(2.01%)
U.S. Market opens in 19h 49m

Neuronetics, Inc. Fundamental Analysis

Neuronetics, Inc. (STIM) shows moderate financial fundamentals with a PE ratio of -2.68, profit margin of -26.15%, and ROE of -1.39%. The company generates $0.2B in annual revenue with moderate year-over-year growth of 4.96%.

Key Strengths

Cash Position32.88%
PEG Ratio-0.10
Current Ratio2.02

Areas of Concern

ROE-1.39%
Operating Margin-21.08%
We analyze STIM's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -144.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-144.0/100

We analyze STIM's fundamental strength across five key dimensions:

Efficiency Score

Weak

STIM struggles to generate sufficient returns from assets.

ROA > 10%
-27.55%

Valuation Score

Excellent

STIM trades at attractive valuation levels.

PE < 25
-2.68
PEG Ratio < 2
-0.10

Growth Score

Weak

STIM faces weak or negative growth trends.

Revenue Growth > 5%
4.96%
EPS Growth > 10%
-31.43%

Financial Health Score

Moderate

STIM shows balanced financial health with some risks.

Debt/Equity < 1
4.04
Current Ratio > 1
2.02

Profitability Score

Weak

STIM struggles to sustain strong margins.

ROE > 15%
-138.87%
Net Margin ≥ 15%
-26.15%
Positive Free Cash Flow
No

Key Financial Metrics

Is STIM Expensive or Cheap?

P/E Ratio

STIM trades at -2.68 times earnings. This suggests potential undervaluation.

-2.68

PEG Ratio

When adjusting for growth, STIM's PEG of -0.10 indicates potential undervaluation.

-0.10

Price to Book

The market values Neuronetics, Inc. at 4.67 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.67

EV/EBITDA

Enterprise value stands at -1.76 times EBITDA. This is generally considered low.

-1.76

How Well Does STIM Make Money?

Net Profit Margin

For every $100 in sales, Neuronetics, Inc. keeps $-26.15 as profit after all expenses.

-26.15%

Operating Margin

Core operations generate -21.08 in profit for every $100 in revenue, before interest and taxes.

-21.08%

ROE

Management delivers $-1.39 in profit for every $100 of shareholder equity.

-1.39%

ROA

Neuronetics, Inc. generates $-27.55 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.55%

Following the Money - Real Cash Generation

Operating Cash Flow

Neuronetics, Inc. generates limited operating cash flow of $-20.53M, signaling weaker underlying cash strength.

$-20.53M

Free Cash Flow

Neuronetics, Inc. generates weak or negative free cash flow of $-21.34M, restricting financial flexibility.

$-21.34M

FCF Per Share

Each share generates $-0.31 in free cash annually.

$-0.31

FCF Yield

STIM converts -20.11% of its market value into free cash.

-20.11%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.68

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.10

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.67

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.71

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

4.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.02

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.39

vs 25 benchmark

ROA

Return on assets percentage

-0.28

vs 25 benchmark

ROCE

Return on capital employed

-0.28

vs 25 benchmark

How STIM Stacks Against Its Sector Peers

MetricSTIM ValueSector AveragePerformance
P/E Ratio-2.6828.45 Better (Cheaper)
ROE-138.87%763.00% Weak
Net Margin-26.15%-45265.00% (disorted) Weak
Debt/Equity4.040.34 Weak (High Leverage)
Current Ratio2.022795.60 Strong Liquidity
ROA-27.55%-16588.00% (disorted) Weak

STIM outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Neuronetics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-30.77%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

26.19%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

41.10%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ